Indian firm Bharat Biotech, has announced that the animal trials of its coronavirus vaccine candidate Covaxin were successful.
Bharat Biotech was working towards developing a COVID-19 vaccine along with ICMR.
Indian firm Bharat Biotech announced that the animal trials were successful
The company announced that Covaxin developed antibodies to the virus in monkeys. Bharat Biotech has stated through a tweet that animal testing of its Covid-19 vaccine covaccine has been successful.
Also Read –
“Bharat Biotech proudly announces the animal study results of COVAXIN – These results demonstrate the protective efficacy in a live viral challenge model,” tweeted the Hyderabad-based firm.
Bharat Biotech said in a statement that the results of the study on monkeys showed immunogenicity of the vaccine. Bharat Biotech gave vaccine doses to certain types of monkeys of Macaca mulata species.
The company is currently conducting a phase I/II clinical trial of Covaxin on 1,125 patients at 12 hospitals across the country, including All India Institute of Medical Sciences in New Delhi and Patna, King George Hospital in Visakhapatnam, Nizam’s Institute of Medical Sciences in Hyderabad and PGIMS in Rohtak.
The company completed the first phase of human trials in the past. The second phase of Covaxin trial has started on Monday 7 September.
Covaxin is an ‘inactivated’ vaccine of ICMR-Bharat Biotech. It is made up of corona virus particles that were killed so that they could not infect.
This strain of Covid was isolated at Pune’s NIV Lab. Its dose makes antibodies against the virus in the body.